{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T16:33:42Z","timestamp":1774802022242,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.pharma.2017.06.003","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T18:16:09Z","timestamp":1501870569000},"page":"420-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bags"],"prefix":"10.1016","volume":"75","author":[{"given":"V.","family":"Vieillard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Astier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2017.06.003_bib0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ctrv.2006.10.005","article-title":"Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario","volume":"33","author":"Cheung","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pharma.2017.06.003_bib0130","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2017.06.003_bib0135","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2017.06.003_bib0140","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","article-title":"Stability of protein pharmaceuticals: an update","volume":"27","author":"Manning","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharma.2017.06.003_bib0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization, and formulation of liquid protein pharmaceuticals","volume":"185","author":"Wang","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2017.06.003_bib0150","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1023\/A:1025771421906","article-title":"Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation","volume":"20","author":"Chi","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.pharma.2017.06.003_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.20727","article-title":"Antibody structure, instability, and formulation","volume":"96","author":"Wang","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2017.06.003_bib0160","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/jps.20740","article-title":"Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization","volume":"95","author":"Wakankar","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2017.06.003_bib0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pharma.2011.07.002","article-title":"Guidelines for the practical stability studies of anticancer drugs: a European consensus conference","volume":"69","author":"Bardin","year":"2011","journal-title":"Ann Pharm Fr"},{"issue":"1\u20132","key":"10.1016\/j.pharma.2017.06.003_bib0170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2012.06.063","article-title":"Long-term stability of diluted solutions of the monoclonal antibody rituximab","volume":"436","author":"Paul","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2017.06.003_bib0175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jps.22739","article-title":"Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions","volume":"101","author":"Sreedhara","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2017.06.003_bib0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2016.01.008","article-title":"Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues","volume":"58","author":"Bardo-Brouard","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.pharma.2017.06.003_bib0185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2013.02.039","article-title":"Long-term physico-chemical stability of diluted trastuzumab","volume":"448","author":"Paul","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharma.2017.06.003_bib0190","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejpb.2004.12.004","article-title":"Induction and analysis of aggregates in a liquid IgG1-antibody formulation","volume":"59","author":"Mahler","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.pharma.2017.06.003_bib0195","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2009.06.001","article-title":"Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress","volume":"38","author":"Hawe","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharma.2017.06.003_bib0200","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0003-2697(82)90512-7","article-title":"Simultaneous determination of tyrosine and tryptophan residues in proteins by second-derivative spectroscopy","volume":"126","author":"Servillo","year":"1982","journal-title":"Anal Biochem"},{"key":"10.1016\/j.pharma.2017.06.003_bib0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0003-2697(80)90117-7","article-title":"Second-derivative spectroscopy of proteins: studies on tyrosyl residues","volume":"106","author":"Balestrieri","year":"1980","journal-title":"Anal Biochem"},{"issue":"3","key":"10.1016\/j.pharma.2017.06.003_bib0210","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jps.20753","article-title":"Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability","volume":"96","author":"Harn","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2017.06.003_bib0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pharma.2016.08.002","article-title":"One-month stability study of a biosimilar of infliximab (Remsima\u00ae) after dilution and storage at 4\u00b0C and 25\u00b0C","volume":"75","author":"Vieillard","year":"2017","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.pharma.2017.06.003_bib0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0141-8130(96)01150-6","article-title":"Destabilization of human serum albumin by polyethylene glycols studied by thermodynamical equilibrium and kinetic approaches","volume":"20","author":"Farruggia","year":"1997","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.pharma.2017.06.003_bib0225","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jpba.2016.06.007","article-title":"methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure","volume":"128","author":"Chen","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2017.06.003_bib0230","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1006\/jmbi.2001.4821","article-title":"Solution structure of the catalytic domain of gamma delta resolvase. Implications for the mechanism of catalysis","volume":"310","author":"Pan","year":"2001","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pharma.2017.06.003_bib0235","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40259-013-0036-3","article-title":"Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab","volume":"27","author":"Visser","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.pharma.2017.06.003_bib0240","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nbt.1839","article-title":"Acceptable changes in quality attributes of glycosylated biopharmaceuticals","volume":"29","author":"Schiest","year":"2011","journal-title":"Nature Biotech"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450917301062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450917301062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:33:21Z","timestamp":1757720001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450917301062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0003450917301062"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2017.06.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bags","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2017.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}